Document:

<PAGE>

                                                                   EXHIBIT 10.20

        [CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS
        AGREEMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH
                                THE COMMISSION.]

                              TECHNOLOGY AGREEMENT

                      GENERATION OF KNOCKOUT MOUSE STRAINS

                                     between

                                 DELTAGEN, INC.
                                1031 Bing Street
                              San Carlos, CA 94070

                                       and

                                MERCK & CO, INC.
                                 One Merck Drive
                                  P.O. Box 100
                    Whitehouse Station, New Jersey 08889-0100

WHEREAS, Deltagen, Inc. ("Deltagen") and Merck ("Merck"), (collectively,
"Parties") seek to collaborate in scientific research related to generation of
Knockout Mouse strains;

WHEREAS, Deltagen has knowledge and experience in research and generation of
Knockout Mice; and

WHEREAS, Merck wishes to obtain Knockout Mice generated by Deltagen according to
specifications agreed by the Parties.

1.       DEFINITIONS

As used in this.Agreement the following terms shall have the meanings as
specified:

1.1      "Merck Affiliate" shall mean (i) any corporation or business entity of
         which fifty percent (50%) or more of the securities or other ownership
         interest representing the equity, the voting stock or general
         partnership interest are owned, controlled or held, directly or
         indirectly, by Merck; or (ii) any corporation or business entity which,
         directly or indirectly, owns, controls, or holds 50 percent (50%) (or
         the maximum ownership permitted by law) or more of the securities or
         other ownership interest representing the equity, the voting stock or,
         if applicable, the general partnership interest, of Merck.

1.2      "Effective Date" shall mean the date of the signature of the
         representative of the last of the Parties to execute this Agreement.

1.3      "Joint Patents" shall mean all patent and patent applications,
         worldwide, for subject matter which is jointly developed during the
         course of this Agreement by both Deltagen and Merck and which is useful
         or necessary in the generation of the Knockout Mice under this
         Agreement.

* * *  Confidential material redacted and separately filed with the Commission.

<PAGE>

1.4      "Joint Technology" shall mean all know-how and technology related to
         the generation of Knockout Mice as well as biological, molecular
         biological and genetic work and technology in each case, which is
         developed jointly hereunder by Deltagen and Merck and which is useful
         in the generation of the Knockout Mice under this Agreement.

1.5      "Knockout Mice" shall mean a line of * * * developed for and delivered
         to Merck as set forth in Article 2 below, having a * * *.

1.6      "Knockout Mouse Project" shall mean the creation, testing and
         generation, by Deltagen, of Knockout Mice.

1.7      * * *.

1.8      * * *.

1.9      * * *.

1.10     * * *

1.11     "Milestone Payments" shall mean those payments set forth at Appendix A
         attached hereto.

1.12     * * *.

1.13     * * *.

1.14     "Standard Procedure" shall mean the set of procedures described in
         Appendix A, with respect to "Milestone 1" through "Milestone 5."

2.       RESEARCH AND WORK TO BE CONDUCTED

2.1      Deltagen shall conduct one or more Knockout Mouse Projects at the
         request of Merck on the terms and conditions of this Agreement. Merck
         will request Deltagen in writing to begin work on each Knockout Mouse
         project to be conducted under this Agreement, such written notice to be
         provided to Deltagen by an authorized representative of Merck in the
         form set forth in Appendix B. Deltagen shall have the right to evaluate
         such request and the information provided to Deltagen by Merck under
         Section 2.3 below, to determine whether such requested Knockout Mouse
         project is feasible. If, after good faith discussion with Merck,
         Deltagen reasonably determines that such project is not technically
         feasible, within the parameters of Appendix A, Deltagen shall so advise
         Merck in writing and shall not be required to undertake such project.

2.2      For each Knockout Mouse Project, Deltagen will use reasonable efforts
         to complete each Milestone in a timely fashion, as defined in Appendix
         A.

2.3      Deltagen shall undertake up to * * * Knockout Mice Projects according
         to the terms and conditions set forth in this Agreement. To initiate
         each Knockout Mouse project the

* * *  Confidential material redacted and separately filed with the Commission.

                                       2
<PAGE>

         parties agree to undertake, Deltagen and Merck will establish a
         timetable for each project Milestone, and Merck shall:

         2.3.1    Identify to Deltagen in writing each Knockout Mouse Project to
                  be initiated;

         2.3.2    Disclose in writing to Deltagen * * * useful in completing
                  Milestone 1 with respect to each Knockout Mouse Project, as
                  defined at Appendix A;

         2.3.3    Consult with Deltagen to identify * * * for such Knockout
                  Mouse Project;

         2.3.4    Transfer to Deltagen * * * which may be * * *; and

         2.3.5    Identify and notify Deltagen in writing of the specific gene
                  sequence for each Knockout Mouse Project for which Deltagen is
                  requested by Merck to produce a Knockout Mouse. Merck shall be
                  solely responsible for identifying and notifying Deltagen in
                  writing of the specific gene sequence for each Knockout Mouse
                  project.

2.4      For purposes of the schedule set forth in Appendix A, each Knockout
         Mouse Project conducted hereunder shall commence fifteen (15) days
         after Deltagen's receipt from Merck of all information and materials
         set forth in Section 2.3 relating to such Knockout Mouse Project.

2.5      Each Knockout Mouse Project shall be deemed complete upon Deltagen's
         completion of Milestone 5 (see Appendix A) and Deltagen's delivery
         after the birth of the first generation of Knockout Mice of at least
         * * *. Deltagen, for a period of six (6) months following the
         completion of each Milestone 5 for each Knockout Mouse Project,
         shall retain a small backup colony of * * * from such project
         consisting of * * * for each Knockout Mouse Project). With respect
         to such backup colonies of Knockout Mice, Merck shall for a period
         not to exceed six (6) months following completion of Milestone 5 pay
         to Deltagen * * *. At Merck's request, Deltagen will transfer the
         mice to Merck. All reasonable transportation and transfer costs
         shall be paid by Merck. If Merck does not request transfer within
         the six month period, Deltagen, following Deltagen's written
         notification to Merck, shall dispose of the mice in accordance with
         all applicable laws and regulations.

2.6      Deltagen shall use reasonable efforts to * * * and to generate Knockout
         Mice under each Knockout Mouse project according to the specification
         of Merck as set forth in Section 2.3 above.

* * *  Confidential material redacted and separately filed with the Commission.

                                       3
<PAGE>

2.7      Deltagen shall, at all times in its animal care and handling activities
         related to this Agreement, comply with all applicable Federal, State
         and local laws and regulations, and assure that Deltagen animal
         facilities meet or exceed minimum accreditation standards * * *.

3.       PAYMENTS

3.1      Within thirty (30) days after the Effective Date, Merck shall pay to
         Deltagen * * * for the * * * calculated in accordance with Appendix A.
         Such payment shall be * * * Milestones as set forth in Appendix A.

3.2      Merck shall pay to Deltagen for each Milestone completed by Deltagen:

         3.2.1    The Milestone Payments set forth in Appendix A are for all
                  Knockout Mouse Projects wherein a * * * is requested by Merck
                  under Section 2.3 above, so long as the Project is initiated
                  during the term of this Agreement. The Milestone Payments for
                  all Knockout Mouse Projects wherein * * * is requested, shall
                  be determined on a case-by-case basis, upon good faith
                  negotiations between the parties and shall be mutually agreed
                  to in writing by the parties.

3.3      Deltagen shall inform Merck, in writing, of its completion of each
         Milestone, as defined in Appendix A. In such written notice, Deltagen
         shall certify that the Knockout Mice delivered to Merck conform to the
         Knockout Mice specifications for each Knockout Mouse Project set forth
         in Appendix A, and Deltagen shall provide with each delivery of
         Knockout Mice to Merck all of the information and data described in
         Appendix A for each Knockout Mouse Project.

3.4      Subject to payment credit as provided in Section 3.1, Merck shall pay
         all Milestones to Deltagen within thirty (30) days after Merck's
         receipt of written representation from Deltagen of Deltagen's
         completion of Milestones in compliance with the terms of this
         Agreement.

4.       ON-SITE CONSULTATION

4.1      Merck may reasonably request on-site consultations by Deltagen
         personnel relating directly to projects under this Agreement. Merck
         will reimburse Deltagen for all reasonable and reasonably documented
         travel expenses associated with such onsite consultations by Deltagen
         personnel.

4.2      Upon reasonable notice to Deltagen and upon reasonable terms and
         conditions agreed upon by Deltagen and Merck, Merck shall be entitled
         to perform site visits to Deltagen facilities involved in the Knockout
         Mouse Projects to inspect the facilities for compliance with generally
         accepted scientific and animal care procedures including, but not
         limited to those set forth in Appendix A and Section 2.7 above.

* * *  Confidential material redacted and separately filed with the Commission.

                                       4
<PAGE>

5.       TERM AND TERMINATION

5.1      The term of this Agreement shall commence on the Effective Date and
         shall remain in effect until the earlier of either (a) termination of
         this Agreement pursuant to the completion by Deltagen of all Milestones
         under this Agreement or (b) two (2) years from the Effective Date;
         provided, however, that all applicable obligations of Deltagen and
         Merck under this Agreement shall remain in force with respect to any
         Knockout Mouse Project requested by Merck and initiated by Deltagen
         which remains ongoing prior to the date set forth in subsection (b) of
         this paragraph.

5.2      * * *. Should Merck at any time during the Knockout Mouse Project
         terminate the development and creation or completion of a specific
         Knockout Mouse Project, Merck shall make the next Milestone Payment
         corresponding to that work being conducted by Deltagen to complete such
         Milestone at the time of termination, as if Deltagen had completed the
         Milestone, regardless of whether such Milestone has been reached.

5.3      Deltagen may terminate a Knockout Mouse Project upon Deltagen's
         identification of technical difficulty beyond the reasonable control of
         Deltagen which would prevent Deltagen from completing the Project using
         commercially reasonable efforts, provided that Deltagen has informed
         Merck, in writing, of the details of such technical difficulty, and the
         parties have had an opportunity to discuss the circumstances to attempt
         to resolve the technical difficulty in a reasonable manner. Merck is
         not entitled to a refund of any past Milestone payments paid if a
         project is terminated as the result of technical difficulty beyond the
         control of Deltagen.

5.4      If either of the Parties is in breach of any obligation under this
         Agreement, the party complaining of said breach shall give written
         notice to the breaching party to remedy such breach. If the breach is
         not remedied within 60 days following the receipt of such notice, the
         party complaining of breach may terminate this Agreement upon written
         notice to the other party at any time and with immediate effect. Any
         such termination will be without prejudice to any other rights which
         the party complaining of breach may have as a result of any breach of
         this Agreement.

6.       CONFIDENTIALITY

6.1      Each party shall treat all information which has been received from the
         other party as strictly confidential ("Information"), and shall not to
         make such Information available to any third party without the express
         prior written consent of the other party and only to use such
         Information for the purposes expressly provided in this Agreement. For
         this purpose, employees and consultants of the parties shall be bound
         by obligations of confidentiality and secrecy no less strict than those
         set out herein and shall not be regarded as third parties.

6.2      The above obligations shall not apply or cease to apply to Information
         which the recipient can show:

         (a)      has become generally available to the public other than
                  through violation of this undertaking;

* * *  Confidential material redacted and separately filed with the Commission.

                                       5

<PAGE>

         (b)      was already in the recipient's rightful possession prior to
                  its acquisition from the disclosing party;

         (c)      was developed independently of information received from the
                  disclosing party;

         (d)      has been lawfully received from a third party, under no
                  obligation to maintain the Information as confidential; or

         (e)      is required to be disclosed by law or court order, provided
                  that notice is promptly delivered to the other party in order
                  to provide an opportunity to challenge or limit such
                  disclosure.

         A statutory obligation to disclose confidential information to
         governmental authorities in connection with the Food and Drug
         Administration product registration procedures is not subject to this
         secrecy obligation.

6.3      This obligation of confidentiality shall survive the expiration and/or
         termination of this Agreement for a period of * * *.

6.4      Upon expiration or termination of this Agreement, or at any time upon
         the disclosing party's written request, the receiving party shall
         destroy, or at the written request of the disclosing party, deliver to
         the disclosing party any and all Information (including copies)
         received or generated hereunder, except that the receiving party may,
         for archival purposes, maintain one copy of the Information in its
         confidential legal files.

7.       OWNERSHIP OF RIGHTS

7.1      * * *.

7.2      * * *.

7.3      * * *.

7.4      * * *.

7.5      * * *.

7.6      * * *.

* * *  Confidential material redacted and separately filed with the Commission.

                                       6
<PAGE>

8.       MISCELLANEOUS

8.1      PUBLICATION. If Merck publishes any information, data or material
         regarding the Knockout Mice contemplated under this Agreement, Merck
         shall acknowledge within the publication, the contribution of Deltagen
         to the generation of such mouse or mice.

8.2      FORCE MAJEURE. Neither party shall be liable for its failure to perform
         its obligations under this Agreement due to contingencies beyond its
         reasonable control, including but not limited to strikes, riots, wars,
         fire, flood, accident, labor disputes, embargoes, inability to obtain
         export or import license, acts of God, or acts in compliance with any
         governmental or state law, regulation or other.

8.3      AMENDMENTS. Amendments or modifications of this Agreement may only be
         made by a written Agreement executed by both Parties.

8.4      NOTICES. All notices required or permitted hereunder shall be given in
         writing and sent postage prepaid by first class certified or registered
         mail, or sent by a nationally recognized express courier service, or
         hand delivered at the following addresses:

                           If to Deltagen:
                           * * *

                           If to Merck:
                           * * *

8.5      REPRESENTATIONS AND WARRANTIES.  Each party represents and warrants
         that:

         8.5.1    It will use commercially reasonable efforts to complete its
                  obligations under this Agreement in compliance with any and
                  all applicable federal, state, or local laws, regulations and
                  guidelines.

         8.5.2    * * *.

8.6      * * *.

8.7      APPLICABLE LAW AND VENUE. This Agreement shall be governed by and
         construed in accordance with the laws of the State of California as
         though made and performed in said state without regard to its conflict
         of law revisions.

8.8      COUNTERPARTS. This Agreement may be executed in counterparts, each of
         which shall be deemed an original, but all of which together shall
         constitute one and the same instrument.

8.9      U.S. EXPORT LAWS AND REGULATIONS. Without limitation, each party shall
         comply with all laws and regulations of the United States relating to
         the export of biological materials, products and technical information.

8.10     ENTIRE AGREEMENT. This Agreement contains the entire understanding of
         the parties with respect to the subject matter hereof. All express or
         implied Agreements -and

* * *  Confidential material redacted and separately filed with the Commission.

                                       7
<PAGE>

         understandings, either oral or written, heretofore made are expressly
         superseded by this Agreement.

8.11     INDEPENDENT CONTRACTORS. It is expressly agreed that Deltagen and Merck
         shall be independent contractors and that the relationship between the
         two parties shall not constitute a partnership, joint venture or
         agency. Neither Deltagen nor Merck shall have the authority to make any
         statements, representations or commitments or any kind, or to take any
         action, which shall be binding on the other, without the prior consent
         of the party to do so.

8.12     WAIVER. The waiver by either party of any right hereunder or the
         failure to perform or of a breach by the other party shall not be
         deemed a waiver of any other right hereunder or of any other breach or
         failure by said other party whether of a similar nature or otherwise.

* * *  Confidential material redacted and separately filed with the Commission.

                                       8
<PAGE>

AGREED AND ACCEPTED:

DELTAGEN, INC.                            MERCK & CO., INC.

BY   William Mathews                      BY C. Thomas Caskey

NAME:  William Matthews                   NAME:  C. Thomas Caskey

TITLE  President                          TITLE  Senior Vice President, Research

DATE  July 13th, 1998                     DATE  July 10, 1998

* * *  Confidential material redacted and separately filed with the Commission.

                                       9
<PAGE>

                                   APPENDIX A

[3 pages of milestone descriptions redacted and filed separately with the
Commission]

                                      * * *

* * *  Confidential material redacted and separately filed with the Commission.

                                       10
<PAGE>

                                   APPENDIX B

     FORM NOTIFICATION LETTER FOR INITIATION OF A NEW KNOCKOUT-MOUSE PROJECT

                               (Template follows)
                               (Merck letterhead)

Date

Bill Matthews, Ph.D.
President
Deltagen, Inc.
1031 Bing Street
San Carlos, CA 94070

Dear Bill,

This letter is to provide notice to Deltagen of Merck's request to Deltagen to
initiate work on a Knockout Mouse Project under the terms and conditions of the
Technology Agreement between Deltagen, Inc. and Merck, dated
_____________________ (the "Agreement"), including, but not limited to, the
confidentiality obligations of the Agreement. The Knockout Mouse Project to be
initiated is described as follows:

The Merck contact scientist for technical information regarding the project will
be:

Merck requests that Deltagen begin to work to develop the above described
Knockout Mouse on the terms and conditions of the above-referenced Agreement.

Sincerely,

Merck's Signatory

Agreed,

-------------------------------------
Deltagen

* * *  Confidential material redacted and separately filed with the Commission.

                                       11
<PAGE>

                                  AMENDMENT TO
                              TECHNOLOGY AGREEMENT

         THIS AMENDMENT TO TECHNOLOGY AGREEMENT, dated as of December 21, 1999
(this "Amendment"), is entered into between DELTAGEN, INC. ("Deltagen"), having
a place of business at 1003 Hamilton Avenue, Menlo Park, California 94025, and
MERCK & CO, INC. ("Merck"), having a place of business at One Merck Drive, P.O.
Box 100, Whitehouse Station, New Jersey 08889-0100, and is made with reference
to the following facts:

         A.       WHEREAS, the parties entered into that certain Technology
Agreement on July 13, 1998 (the "Technology Agreement").

         B.       WHEREAS, the parties desire to modify the Technology Agreement
to increase the number of Knockout Mice under the Technology Agreement, to
extend the term of the Technology Agreement and to modify such other terms as
set forth below.

         NOW, THEREFORE, in consideration of the mutual covenants set forth
below and other valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the parties hereby amend the License Agreement, and agree
as follows:

1.       AMENDMENTS.

1.1      The first sentence of Section 2.3 is hereby restated in its entirety as
         follows:

                    Deltagen shall undertake * * * Knockout Mice Projects
                    according to the terms and conditions set forth in this
                    Agreement.

1.2               AMENDMENT TO SECTION 3.1. Section 3.1 is hereby restated in
                     its entirety to read as follows:

                    Merck shall pay to Deltagen * * * of the total estimated
                    cost for the * * * Knockout Mouse Projects and the * * *
                    Knockout Mouse Projects as set forth in Appendix A. Such
                    payment shall be nonrefundable and shall be credited against
                    the Milestones as set forth in Appendix A.

1.3               AMENDMENT TO SECTION 5.1. Section 5.1 is hereby restated in
                     its entirety to read as follows:

                   The term of this Agreement shall commence on the Effective
                   Date and shall remain in effect until the earlier of either
                   (a) termination of this Agreement pursuant to the completion
                   by Deltagen of all Milestones under this Agreement as amended
                   or (b) December 31, 2002; provided however, that all
                   applicable obligations of Deltagen and Merck under this
                   Agreement shall remain in force with respect to any Knockout
                   Mouse Project requested by Merck and initiated by

* * *  Confidential material redacted and separately filed with the Commission.

                                       12
<PAGE>

                   Deltagen which remains ongoing prior to the date set forth in
                   subsection (b) of this paragraph.

1.4      AMENDMENT TO SECTION 8.4. The second paragraph of Section 8.4,
         beginning with the phrase "If to Deltagen" and ending with "6823" is
         hereby modified as follows:

                   If to Deltagen:

                   * * *

1.5      AMENDMENT TO APPENDIX A. Appendix A is hereby restated in its entirety
         as set forth in Appendix A attached hereto.

2.       INITIATION PAYMENT. IN PARTIAL CONSIDERATION FOR THIS AMENDMENT, WITHIN
         THIRTY (30) DAYS AFTER THE DATE OF THIS AMENDMENT, MERCK SHALL PAY TO
         DELTAGEN THE * * * SET FORTH IN APPENDIX A OF THIS AGREEMENT AS
         AMENDED.

3.       CONTINUING EFFECT. THIS AMENDMENT SHALL BE EFFECTIVE FOR ALL PURPOSES
         AS OF THE DATE FIRST SET FORTH ABOVE. EXCEPT AS OTHERWISE EXPRESSLY
         MODIFIED BY THIS AMENDMENT, THE TECHNOLOGY AGREEMENT SHALL REMAIN IN
         FULL FORCE AND EFFECT IN ACCORDANCE WITH ITS TERMS.

4.       DEFINED TERMS. ALL TERMS USED, BUT NOT DEFINED, IN THIS AMENDMENT SHALL
         HAVE THE RESPECTIVE MEANINGS AS SET FORTH IN THE TECHNOLOGY AGREEMENT.

[Intentionally Left Blank]

* * *  Confidential material redacted and separately filed with the Commission.

                                       13
<PAGE>

5.       COUNTERPARTS. THIS AMENDMENT MAY BE EXECUTED IN COUNTERPARTS, EACH OF
         WHICH SHALL BE DEEMED AN ORIGINAL, BUT ALL OF WHICH TOGETHER SHALL
         CONSTITUTE ONE AND THE SAME INSTRUMENT.

         IN WITNESS WHEREOF, the parties have executed this Amendment as of the
date first set forth above.

                                    DELTAGEN, INC.

                                    By: /s/ Augustine Yee
                                        ---------------------------------------

                                    Its: Vice President Corporate Development
                                        ---------------------------------------

                                    MERCK & CO, INC.

                                    By: /s/ Anthony Ford-Hutchinson
                                        ---------------------------------------
                                           Anthony Ford-Hutchinson

                                    Its:  Senior Vice President
                                        ---------------------------------------
                                          Basic Research
                                        ---------------------------------------

* * *  Confidential material redacted and separately filed with the Commission.

                                       14
<PAGE>

                             APPENDIX A TO AMENDMENT

[5 pages of milestone descriptions redacted and filed separately with the
Commission]

                                      * * *

* * *  Confidential material redacted and separately filed with the Commission.

                                       15<PAGE>

                                                                     EXHIBIT 4.6

         This Security Has Not Been Registered Under The Securities Act Of 1933,
As Amended, Or Any State Securities Laws. It May Not Be Transferred, Assigned,
Sold Or Offered for Sale Except Pursuant To An Effective Registration Statement
Under Said Act And Any Applicable State Securities Law Or An Opinion Of Counsel,
In Form And Substance Reasonably Acceptable To The Company, That Registration Is
Not Required Because Of An Applicable Exemption From Such Registration
Requirements.

         The Rights Of The Holder Of This Debenture Are Subject To The Terms Of
A Subordination Agreement, Dated February 23, 2000, Among The Senior Lenders (As
Defined Therein) And, Among Others, The Holder Of This Debenture (the
"Subordination Agreement").

         NO.  2                                                      $2,500,000

         DATED: FEBRUARY 23, 2000

                       ADVANCED COMMUNICATIONS GROUP, INC.

                 5% CONVERTIBLE DEBENTURE DUE FEBRUARY 23, 2006

         THIS DEBENTURE ("Debenture") is one of a duly authorized issue of
Debentures of ADVANCED COMMUNICATIONS GROUP, INC. (the "Company"), a corporation
duly organized and existing under the laws of the State of Delaware, designated
as the Company's 5% Convertible Debentures Due February 23, 2006, in an
aggregate principal amount of Twenty Million U.S. Dollars (U.S. $20,000,000)
(the "Debenture").

         FOR VALUE RECEIVED, the Company promises to pay to Elliott Associates,
L.P. the initial holder hereof, or its order (including successors-in-interest,
the "Holder"), the principal sum of TWO MILLION FIVE HUNDRED U.S. DOLLARS (U.S.
2,500,000) on February 23, 2006 (the "Maturity Date") and to pay interest on the
principal sum outstanding under this Debenture ("Outstanding Principal Amount"),
at the rate of 5% per annum, compounded semi-annually, payable in arrears on the
first day of January and July of each year (each an "Interest Payment Date"),
with the first such payment due on July 1, 2000. Interest shall accrue daily
commencing on the date hereof and shall continue until payment in full of all
amounts due under this Debenture. The interest so payable will be paid to the
person in whose name this Debenture is registered on the records of the Company
regarding registration and transfers of the Debenture (the "Debenture
Register"). Capitalized terms used herein and not otherwise defined shall have
the meanings set forth in the Convertible Debenture Purchase Agreement dated as
of February 23, 2000 between the Company and the Holder (the "Purchase
Agreement") or the Registration Rights Agreement dated as of February 23, 2000
between the Company and the Holder (the "Registration Rights Agreement").

<PAGE>

         The principal of, interest on, and default payments (defined below) in
respect of this Debenture are payable in such coin or currency of the United
States as of the time of payment is legal tender for payment of public and
private debts, at the address last appearing on the Debenture Register of the
Company as designated in writing by the Holder hereof from time to time;
PROVIDED, HOWEVER, that, in lieu of paying such interest in coin or currency,
the Company may, at its option (provided (i) no Interfering Event (as defined in
the Registration Rights Agreement) then exists and (ii) it gives at least
fifteen (15) business days notice prior to an Interest Payment Date), pay
interest on this Debenture for any Interest Payment Date by adding the amount
thereof to the Outstanding Principal Amount due under this Debenture ("PIK
Interest"), pursuant to an irrevocable statement in the form of EXHIBIT 2 hereto
("PIK Statement") delivered at least fifteen (15) business days prior to the
Interest Payment Date on which the Company plans to pay such PIK Interest and
effective for such Interest Payment Date only. If neither the cash interest due
hereunder is paid when due, nor the PIK Statement delivered, to the Holder as
provided above, the Company shall no longer have the right to choose the PIK
Interest option on that Interest Payment Date or any future Interest Payment
Dates and the Holder may elect either cash interest or PIK Interest hereunder at
its option. Any PIK Interest when so added to the Outstanding Principal Amount
due under this Debenture shall, for all purposes of this Debenture, be deemed to
be part of the principal indebtedness evidenced by this Debenture including,
without limitation, for purposes of determining interest payable hereunder after
the applicable Interest Payment Date for which such PIK Statement is delivered
by the Company and amounts convertible into Common Shares hereunder after the
applicable Interest Payment Date for which such PIK Statement is delivered by
the Company.

         The Company will pay any principal due and all accrued and unpaid
interest due upon this Debenture to the person that is the Holder of this
Debenture on the records of the Company as of the applicable Interest Payment
Date and addressed to such Holder at the last address appearing on the Debenture
Register.

         The Outstanding Principal Amount and interest due hereunder shall bear
interest, from and after the day following the occurrence and during the
continuance of an Event of Default hereunder, at the rate equal to the lower of
the Citibank Prime Rate per annum plus six (6%) percent or the highest rate
permitted by law; PROVIDED that the interest rate of this Debenture shall not be
reduced below 5% as a result of this provision. The Holder shall have the option
to receive such interest as PIK Interest or cash interest and shall exercise its
option by delivering to the Company a statement in a form substantially similar
to the PIK Statement which shall be effective until the Holder delivers an
additional statement to the contrary. If the Holder elects to receive the
interest in cash, it shall be payable on demand.

         Additional cash payments (referred to as "default payments") may be
required pursuant to the Registration Rights Agreement if there occurs an
"Interfering Event" (as defined therein), or pursuant to the Purchase Agreement
under the terms set forth in Section 3.14 therein. Such default payments, if not
paid in cash when due, may be treated by the Holder in its sole discretion as
being added to the Outstanding Principal Amount due under this Debenture.

                                       2
<PAGE>

         Subject to applicable law, any interest otherwise payable that is not
paid for any applicable period because it would exceed the highest rate
permitted by law shall become payable whenever the payment thereof, together
with other interest due for any such subsequent period, would not exceed such
highest legal rate.

         The Holder of this Debenture is entitled to certain rights and remedies
pursuant to the Purchase Agreement and Registration Rights Agreement, including
without limitation provisions requiring mandatory redemption of the Debenture.
This Debenture does not provide voting rights to the Holder.

         This Debenture is subject to the following additional provisions:

         1. DENOMINATION. The Debentures are exchangeable for an equal aggregate
principal amount of Debentures of different denominations, as requested by the
Holder surrendering the same. No service charge will be made for such
registration or transfer or exchange.

         2. TRANSFERS. This Debenture may be transferred or exchanged in the
United States only in compliance with the Securities Act of 1933, as amended
(the "Act") and applicable state securities laws, or applicable exemptions
therefrom. Prior to due presentment for transfer of this Debenture, the Company
may treat the person in whose name this Debenture is duly registered on the
Company's Debenture Register as the owner hereof for the purpose of receiving
payment as herein provided, whether or not this Debenture is overdue.

         3. DEFINITIONS. For purposes hereof the following definitions shall
apply:

                  "CHANGE IN CONTROL TRANSACTION" shall mean the occurrence of
(x) any consolidation or merger of the Company with or into any other
corporation or other entity or person (whether or not the Company is the
surviving corporation), or any other corporate reorganization or transaction or
series of related transactions in which in excess of 50% of the Company's voting
power is transferred through a merger, consolidation, tender offer or similar
transaction, or (y) any person (as defined in Section 13(d) of the Securities
Exchange Act of 1934, as amended (the "Exchange Act")), together with its
affiliates and associates (as such terms are defined in Rule 405 under the Act),
beneficially owns or is deemed to beneficially own (as described in Rule 13d-3
under the Exchange Act without regard to the 60-day exercise period) in excess
of 50% of the Company's voting power, or (z) Richard O'Neal shall fail, for any
reason, to (i) a member of the Board of Directors of the Company, or any
successor of the Company, or (ii) be the "beneficial owner" (as defined in Rule
13d-3 under the Exchange Act), directly or indirectly, of seventy percent or
more of the Common Stock of the Company so owned by him on the Closing Date.
Notwithstanding the foregoing, the acquisition of control by one or Permitted
Holders shall not constitute a Change in Control Transaction, without prejudice
to the Holder's rights under this Debenture or the Purchase Agreement or the
Registration Rights Agreement.

                  "CLOSING DATE" shall mean the date of original issuance of
this Debenture.

                                       3
<PAGE>

                  "CLOSING PRICE" shall mean $14.2063.

                  "COMMON STOCK" shall mean the common stock, par value $0.0001,
of the Company.

                  "CONVERSION NOTICE" shall have the meaning set forth in
Section 5(d).

                  "CONVERSION PRICE" shall have the meaning set forth in Section
5(c).

                  "CONVERSION RATE" shall have the meaning set forth in Section
5(b).

                  "HOLDER CONVERSION DATE" shall have the meaning set forth in
Section 5(d).

                  "MARKET PRICE FOR SHARES OF COMMON STOCK" shall mean the price
of one share of Common Stock determined as follows:

                          (i) If the Common Stock is listed on NYSE, the closing
bid price on such Exchange on the date of valuation;

                          (ii) If the Common Stock is listed on the NASDAQ
National Market System or the American Stock Exchange, the closing bid price on
such exchange on the date of valuation;

                          (iii) If neither (i) nor (ii) apply but the Common
Stock is quoted in the over-the-counter market, another recognized exchange, on
the pink sheets or bulletin board, the lesser of (A) the lowest sales price on
the date of valuation or (B) the mean between the last reported "bid" and
"asked" prices thereof on the date of valuation; and

                          (iv) If neither clause (i), (ii) or (iii) above
applies, the market value as determined by a nationally recognized investment
banking firm or other nationally recognized financial advisor retained by the
Company for such purpose, taking into consideration, among other factors, the
earnings history, book value and prospects for the Company, and the prices at
which shares of Common Stock recently have been traded. Such determination shall
be conclusive and binding on all persons.

                  "PERMITTED HOLDERS" shall have the meaning set forth in the
definition of "Permitted Holders" set forth in Article 1 of the Loan Agreement
between Advanced Communications Group, Inc. and, among others, Bank of America,
N.A., without regard to any amendments thereto; provided, however, that each of
the Consolidation Partners Founding Fund, LLC, Consolidation Partners, L.P.
shall only be deemed a Permitted Holder under this Agreement if such entities or
persons are wholly owned by Richard O'Neal and/or Rod Cutsinger and the only
shareholders of the Acquired Companies (as defined in the Loan Document) which
shall be deemed a Permitted Holder are Richard O'Neal and Rod Cutsinger, except
that such entities and their owners or such

                                       4
<PAGE>

shareholders that are set forth on Schedule 1 hereto shall also be deemed
Permitted Holders.

                  "REDEMPTION NOTICE" shall have the meaning set forth in
Section 6(a).

                  "REDEMPTION PRICE" shall have the meaning set forth in Section
6(a).

                  "RESET" SHALL HAVE THE MEANING SET FORTH IN SECTION 5(C).

                  "RESET PRICING PERIOD" SHALL HAVE THE MEANING SET FORTH IN
SECTION 5(c).

                  "RESTRICTED OWNERSHIP PERCENTAGE" shall have the meaning set
forth in Section 12.

                  "TRADING DAY" shall mean a day on which the Common Stock is
traded on the NYSE or principal exchange on which the Common Stock has been
listed (or any similar organization or agency succeeding such market or
exchange's functions of reporting prices).

         4. CHANGE IN CONTROL, ETC. If at any time there occurs any Change in
Control Transaction, Holder shall be entitled, at its sole option, to have the
Company redeem this Debenture in whole or in part at a redemption price equal to
110% of the Outstanding Principal Amount of this Debenture plus all accrued but
unpaid interest and penalties on this Debenture. Such Holder shall be entitled
to make such election at any time after commencement and up to 10 days after the
effective date of the Change in Control Transaction. For purposes of this
Section 4, the commencement date shall be the day upon which the Change in
Control Transaction was publicly announced.

         5. CONVERSION AT THE OPTION OF THE HOLDER. The Holder of this Debenture
shall have the following conversion rights.

                  (a) HOLDER'S RIGHT TO CONVERT. This Debenture shall be
convertible at any time, in whole or in part, at the option of the Holder
hereof, into fully paid, validly issued and nonassessable shares of Common
Stock. If this Debenture is converted in part, the remaining portion of this
Debenture not so converted shall remain entitled to the conversion rights
provided herein.

                  (b) CONVERSION PRICE FOR HOLDER CONVERTED SHARES. The
Outstanding Principal Amount of this Debenture that is converted into shares of
Common Stock at the option of the Holder shall be convertible into the number of
shares of Common Stock which results from application of the following formula:

                                       5
<PAGE>

                                    P + I + D
                          ------------------------------

                                Conversion Price

         P =      Outstanding Principal Amount of this Debenture submitted for
                  conversion as of the Holder Conversion Date
         I =      accrued but unpaid interest (not previously added to
                  principal) on P as of the Holder Conversion Date
         D =      default payments (not previously added to principal) on P as
                  of the Holder Conversion Date

                          The number of shares of Common Stock into which each
$1,000 principal amount of this Debenture hereto may be converted pursuant to
this paragraph hereof is hereafter referred to as the "Conversion Rate."

                  (c) CONVERSION PRICE. Subject to adjustments pursuant to
Section 7, this Debenture will have an initial conversion price equal to
$15.6269 (such price, as Reset (as defined below) and as adjusted in accordance
with Section 7 of this Debenture Section 3.9 of the Purchase Agreement and
Section 2(b)(i) of the Registration Rights Agreement, shall be referred to
herein as the "Conversion Price").

                          On August 23, 2000, February 23, 2001, August 23, 2001
and February 23, 2002, only if the average of the Market Price for Shares of
Common Stock for the ten (10) Trading Days following such respective date (the
"Reset Pricing Period") is lower than the current Conversion Price, the
Conversion Price shall reset ("Reset") to 100% of such average (subject to
further adjustment in each case). The Conversion Price shall not be increased as
a result of a Reset. The Market Price for Shares of Common Stock shall be
appropriately adjusted for stock splits, reverse splits, stock dividends and
other dilutive events that occur during the Reset Pricing Period.

                          In addition to the foregoing and in addition to any
other rights or remedies which may be available to the Holder hereunder, under
the Purchase Agreement and/or the Registration Rights Agreement, if at any time
(i) by reason of the Subordination Agreement, the Holder is prevented from
exercising its redemption rights or receiving any cash payment due to the Holder
hereunder, under the Purchase Agreement or the Registration Rights Agreement
and/or (ii) the Company fails for any reason to repurchase the Debenture (or
portion thereof, as applicable) or make any cash payment in accordance with the
terms of this Debenture, the Purchase Agreement or the Registration Rights
Agreement, then the Conversion Price shall be subject to further adjustment so
that it shall thereafter be equal to the lesser of (x) the lowest Market Price
for Shares of Common Stock during any of the five (5) days prior to the date
that the Holder submits a Conversion Notice (as defined below) to the Company
and (y) the Conversion Price otherwise applicable at such time, subject to
further adjustment in each case. Provided, however, that at no such time shall
the additional shares issuable as a result of this Section 5(c) result in more
than 400,000 shares (as adjusted for stock splits, reverse splits, stock
dividends and other dilutive events) that would otherwise be issuable based on
the then existing Conversion Price.

                                       6
<PAGE>

                  (d) MECHANICS OF CONVERSION. In order to convert this
Debenture (in whole or in part) into full shares of Common Stock, the Holder (i)
shall give written notice in the form of EXHIBIT 1 hereto (the "Conversion
Notice") by facsimile to the Company at such office that the Holder elects to
convert the principal amount (plus accrued but unpaid interest and default
payments) specified therein, which such notice and election shall be revocable
by the Holder at any time prior to its receipt of the Common Stock upon
conversion, and (ii) as soon as practicable after such notice, shall surrender
this Debenture, duly endorsed, by either overnight courier or 2-day courier, to
the principal office of the Company; PROVIDED, HOWEVER, that the Company shall
not be obligated to issue certificates evidencing the shares of the Common Stock
issuable upon such conversion unless either the Debenture evidencing the
principal amount is delivered to the Company as provided above, or the Holder
notifies the Company that such Debenture(s) have been lost, stolen or destroyed
and promptly executes an agreement reasonably satisfactory to the Company to
indemnify the Company from any loss incurred by it in connection with such lost,
stolen or destroyed Debentures. If a Holder is converting less than the maximum
number of shares it may convert under its Debenture, the Company shall reissue
the Debenture with the appropriate remaining principal amount as soon as
practicable after the Company shall have received the Holder's surrendered
Debenture.

                  The Company shall issue and deliver within three business day
of the delivery to the Company of such Conversion Notice, to such Holder of
Debenture(s) at the address of the Holder, or to its designee, a certificate or
certificates for the number of shares of Common Stock to which the Holder shall
be entitled as aforesaid, together with a calculation of the Conversion Rate and
a Debenture or Debentures for the principal amount of Debentures not submitted
for conversion. The date on which the Conversion Notice is given (the "Holder
Conversion Date") shall be deemed to be the date the Company received by
facsimile the Conversion Notice, and the person or persons entitled to receive
the shares of Common Stock issuable upon such conversion shall be treated for
all purposes as the record holder or holders of such shares of Common Stock on
such date.

                  In lieu of delivering physical certificates representing the
Common Shares issuable upon conversion of Debentures or the Warrant Shares (as
defined in the Purchase Agreement) deliverable upon exercise of Warrants (as
defined in the Purchase Agreement), provided the Company's transfer agent is
participating in the Depository Trust Company ("DTC") Fast Automated Securities
Transfer ("FAST") program, upon request of the holder, the Company shall use its
best efforts to cause its transfer agent to electronically transmit the Common
Shares and Warrant Shares issuable upon conversion or exercise to the Holder, by
crediting the account of Holder's prime broker with DTC through its Deposit
Withdrawal Agent Commission ("DWAC") system. The time periods for delivery
described above shall apply to the electronic transmittals through the DWAC
system. The parties agree to coordinate with DTC to accomplish this objective.
The conversions pursuant to Sections 5 shall be deemed to have been made
immediately prior to the close of business on the Holder Conversion Date. The
person or persons entitled to receive the Common Shares issuable upon such
conversion shall be treated for all purposes as the record holder or holders of
such Common Shares at the close of business on the Holder Conversion Date.

                                       7
<PAGE>

         6. OPTION TO REDEEM.

                  (a) At least five Trading Days prior to the commencement of a
Reset Pricing Period, the Company may state its intention to redeem all, but not
less than all, of the Debentures (all or none) for a cash price equal to the
applicable "Redemption Price" (as defined below) by providing an irrevocable,
written notice (the "Redemption Notice") to the Holder. The Redemption Notice
shall indicate that the Company seeks to redeem the Debenture and shall set the
date for the Company's redemption of the Debenture, which date shall be within
20 Trading Days of the closing of the Reset Pricing Period. The "Redemption
Price" shall be equal to (i) if the Redemption Notice is given to the Holder
prior to the first anniversary of the issuance of this Debenture, 110% of the
Outstanding Principal Amount to be redeemed plus all accrued and unpaid interest
and (ii) if the Redemption Notice is given to the Holder subsequent to such
first anniversary, 115% of the Outstanding Principal Amount to be repurchased
plus all accrued but unpaid interest.

                  (b) A Redemption Notice shall only be effective in the event
that (i) the relevant Reset results in the Conversion Price being less than 50%
of the Closing Price and (ii) the provisions of Section 6.15 of the Purchase
Agreement have been satisfied. If the Conversion Price is less than 50% of the
Closing Price and said provisions have been satisfied, the redemption shall
occur on the date set forth in the Redemption Notice (the "Redemption Date") at
the offices of Holder's counsel. If the Company fails to pay the Redemption
Price in full on the Redemption Date in immediately available funds, (i) the
Company shall lose its right to redeem any Debenture in accordance with this
Section 6(b) and (ii) in addition to any other rights or remedies it may have,
the Holder shall have the right to require the Company to repurchase the
Debenture (or any portion thereof, as selected by the Holder) at a price equal
to 110% of the Redemption Price pursuant to a written notice to the Company.

                  (c) If the relevant Reset does not result in the Conversion
Price being less than 50% of the Closing Price, the Redemption Notice shall be
deemed withdrawn.

         7. STOCK SPLITS; DIVIDENDS; ADJUSTMENTS; REORGANIZATIONS.

                  (a) If the Company, at any time while the Debentures are
outstanding, shall (i) pay a stock dividend or otherwise make a distribution or
distributions on any equity securities (including investments or securities
convertible into or exchangeable for such equity securities) in shares of Common
Stock, (ii) subdivide the outstanding shares of Common Stock into a larger
number of shares, (iii) combine outstanding shares of Common Stock into a
smaller number of shares, the Conversion Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock outstanding
before such event and of which the denominator shall be the number of shares of
Common Stock outstanding after such event. Any adjustment made pursuant to this
Section 7(a) shall become effective immediately after the record date for the
determination of shareholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of
an issuance, a subdivision or a combination.

                                       8
<PAGE>

                  (b) INTENTIONALLY LEFT BLANK.

                  (c) If the Company, at any time while the Debentures are
outstanding, shall distribute to all holders of Shares of Common Stock evidences
of its indebtedness or assets or rights or warrants to subscribe for or purchase
any security (excluding those referred to in Section 7(b) above) then the Holder
shall participate in such distribution on a PRO RATA basis with the holders of
shares of Common Stock entitled to receive such dividend, distribution,
issuance, subdivision or combination as if the Holder held that number of shares
of Common Stock that the Holder would have been entitled to receive hereunder
upon conversion of the Debenture (without regard to Section 12) immediately
prior to the record date fixed for determination of shareholders entitled to
receive such dividend, at the Conversion Price then in existence.

                  (d) In the event that at any time or from time to time after
the Closing Date, the Common Stock issuable upon the conversion of the
Debentures is changed into the same or a different number of shares of any class
or classes of stock, whether by merger, consolidation, recapitalization,
reclassification or otherwise (other than a subdivision or combination of shares
or stock dividend or reorganization provided for elsewhere in this Section 7),
then and as a condition to each such event provision shall be made in a manner
reasonably acceptable to the Holders of Debentures so that each Holder of
Debentures shall have the right thereafter to convert such Debenture into the
kind of stock receivable upon such recapitalization, reclassification or other
change by holders of shares of Common Stock, all subject to further adjustment
as provided herein. In such event, the formulae set forth herein for conversion
and redemption shall be equitably adjusted to reflect such change in number of
shares or, if shares of a new class of stock are issued, to reflect the market
price of the class or classes of stock (applying the same factors used in
determining the Conversion Price) issued in connection with the above described
transaction.

                  (e) Whenever any element of the Conversion Price is adjusted
pursuant to Section 7, the Company shall promptly mail to each Holder of the
Debentures, a notice setting forth the Conversion Price after such adjustment
and setting forth a brief statement of the facts requiring such adjustment.

                  (f) In the event of any taking by the Company of a record date
of the holders of any class of securities for the purpose of determining the
holders thereof who are entitled to receive any dividend or other distribution,
any security or right convertible or exchangeable into or entitling the holder
thereof to receive additional shares of Common Stock, or any right to subscribe
for, purchase or otherwise acquire any shares of stock of any class or any other
securities or property, or to receive any other right, the Company shall deliver
to each Holder of Debentures at least 20 days prior to the date specified
therein, a notice specifying the date on which any such record is to be taken
for the purpose of such dividend, distribution, security or right and the amount
and character of such dividend, distribution, security or right.

         8. FRACTIONAL SHARES. No fractional shares of Common Stock or scrip
representing fractional shares of Common Stock shall be issuable hereunder. The

                                       9
<PAGE>

number of shares of Common Stock that are issuable upon any conversion shall be
rounded up to the nearest whole share.

         9. RESERVATION OF STOCK ISSUABLE UPON CONVERSION.

                  (a) RESERVATION REQUIREMENT. The Company covenants that it
will at all times reserve and keep available out of its authorized and unissued
Common Stock solely for the purpose of issuance upon conversion of the
Debentures as herein provided, free from preemptive rights or any other present
or contingent purchase rights of persons other than the Holders of the
Debentures, 200% of the maximum number of shares of Common Stock as shall be
issuable (taking into account the adjustments and restrictions of Sections 5 and
7 hereof) upon the conversion of all of the Debentures pursuant hereto. The
Company covenants that all shares of Common Stock that shall be so issuable
shall upon issue, be duly and validly authorized, issued and fully paid and
nonassessable. Without in any way limiting the foregoing, so long as any
Debentures remain outstanding the Company agrees to reserve and at all times
keep available solely for purposes of conversion of Debentures such number of
authorized but unissued shares of Common Stock that is set forth in the Purchase
Agreement.

                  (b) DEFICIENCY. If the Company does not have a sufficient
number of shares of Common Stock available to satisfy the Company's obligations
to a Holder of Debentures upon receipt of a Conversion Notice or is otherwise
unable to issue such shares of Common Stock in accordance with the terms of this
Agreement such Holder shall be entitled to the rights and remedies set forth in
the Registration Rights Agreement.

         10. NO REISSUANCE OF THE DEBENTURE. No Debentures acquired by the
Company by reason of redemption, purchase, exchange or otherwise shall be
reissued, and all such Debentures shall be retired.

         11. NO IMPAIRMENT. The Company shall not intentionally take any action
which would impair the rights and privileges of the Debentures set forth herein
or the Holders thereof.

         12. LIMITATIONS ON HOLDER'S RIGHT TO CONVERT.

         (a) Notwithstanding anything to the contrary contained herein, no
Debenture may be converted to the extent that, after giving effect to shares of
Common Stock to be issued pursuant to a Conversion Notice, the total number of
shares of Common Stock deemed beneficially owned by such Holder (other than by
virtue of the ownership of Debentures or ownership of other securities that have
limitations on a Holder's rights to exchange, convert or exercise similar to
those limitations set forth herein), together with all shares of Common Stock
deemed beneficially owned by the holder's "affiliates" (as defined in Rule 144
of the Act) that would be aggregated for purposes of determining whether a group
under Section 13(d) of the Securities Exchange Act of 1934, as amended, exists
(an "aggregation party"), would exceed 9.9% (the "Restricted Ownership
Percentage") of the total issued and outstanding shares of the Company's Common
Stock; PROVIDED that (w) each holder shall have the right at any time and from
time to time to reduce its Restricted Ownership Percentage immediately upon

                                       10
<PAGE>

notice to the Company, (x) each Holder shall have the right at any time and from
time to time, to increase its Restricted Ownership Percentage and otherwise
waive in whole or in part the restrictions of this Section 12(a) upon 61 days'
prior notice to the Company or immediately in the event of the announcement of a
pending or proposed Change in Control Transaction, (y) each holder can make
subsequent adjustments pursuant to (w) or (x) any number of times from time to
time (which adjustment shall be effective immediately if it results in a
decrease in the percentage or shall be effective upon 61 days' prior written
notice or immediately in the event of the announcement of a pending or proposed
Change in Control Transaction if it results in an increase in the percentage)
and (z) each Holder may eliminate or reinstate this limitation at any time and
from time to time (which elimination will be effective upon 61 days' prior
notice and which reinstatement will be effective immediately). Without limiting
the foregoing, in the event of the announcement of a pending or proposed Change
in Control Transaction, any Holder may reinstate immediately (in whole or in
part) the requirement that any increase in its Restricted Ownership Percentage
be subject to 61 days' prior written notice, notwithstanding such Change in
Control Transaction, without imposing such requirement on, or otherwise changing
such Holder's rights with respect to, any other Change in Control Transaction.
For this purpose, any material modification of the terms of a Change in Control
Transaction will be deemed to result in a new Change in Control Transaction. The
term "deemed beneficially owned" as used in this Debenture shall exclude shares
that might otherwise be deemed beneficially owned by reason of the
convertibility of the Debentures. The Company shall provide all Holders with the
earlier of (i) 20 days' prior written notice of any such Change in Control
Transaction, to the extent the Company has prior knowledge of a Change in
Control Transaction; or (ii) notice on the day immediately following the
Company's learning of any such transaction, but only after, in the case of (i)
and (ii), such Change in Control Transaction has been publicly disclosed.

         (b) Each time (a "Covenant Time") the Holder makes a Triggering
Acquisition (as defined below) of shares of Common Stock (the "Triggering
Shares"), the Holder will be deemed to covenant that it will not, during the
balance of the day on which such Triggering Acquisition occurs, and during the
61-day period beginning immediately after that day, acquire additional shares of
Common Stock pursuant to rights-to-acquire existing at that Covenant Time, if
the aggregate amount of such additional shares so acquired (without reducing
that amount by any dispositions) would exceed (x) the Restricted Ownership
Percentage of the number of shares of Common Stock outstanding at that Covenant
Time (including the Triggering Shares) minus (y) the number of shares of Common
Stock actually owned by the Holder at that Covenant Time (regardless of how or
when acquired, and including the Triggering Shares). A "Triggering Acquisition"
means the giving of a Conversion Notice or any other acquisition of Common Stock
by the Holder or an aggregation party; provided, however, that with respect to
the giving of such Conversion Notice, if the associated issuance of shares of
Common Stock does not occur, such event shall cease to be a Triggering
Acquisition and the related covenant under this paragraph shall terminate. At
each Covenant Time, the Holder shall be deemed to waive any right it would
otherwise have to acquire Common Shares to the extent that such acquisition
would violate any covenant given by the Holder under this paragraph. For the
avoidance of doubt:

                                       11
<PAGE>

                  (i) The covenant to be given pursuant to this Section 12(b)
will be given at every Covenant Time and shall be calculated based on the
circumstances then in effect. The making of a covenant at one Covenant Time
shall not terminate or modify any prior covenants.

                  (ii) The Holder may therefore from time to time be subject to
multiple such covenants, each one having been made at a different Covenant Time,
and some possibly being more restrictive than others. The Holder must comply
with all such covenants then in effect.

         13. OBLIGATIONS ABSOLUTE. No provision of this Debenture , the Purchase
Agreement or the Registration Rights Agreement shall alter or impair the
obligation of the Company, which is absolute and unconditional, to pay the
principal of, and interest and default payments on, this Debenture or to issue
shares of Common Stock in response to a Conversion Notice at the time, place and
rate, and in the manner, herein prescribed.

         14. WAIVERS OF DEMAND, ETC. The Company hereby expressly and
irrevocably waives demand and presentment for payment, notice of nonpayment,
protest, notice of protest, notice of dishonor, notice of acceleration or intent
to accelerate, bringing of suit and diligence in taking any action to collect
amounts called for hereunder and will be directly and primarily liable for the
payment of all sums owing and to be owing hereon, regardless of and without any
notice, diligence, act or omission as or with respect to the collection of any
amount called for hereunder.

         15. REPLACEMENT DEBENTURE. In the event that any Holder notifies the
Company that its Debenture(s) have been lost, stolen or destroyed, replacement
Debenture(s) identical in all respects to the original Debenture(s) (except for
registration number and Outstanding Principal Amount, if different than that
shown on the original Debenture(s)), shall be issued to the Holder, provided
that the Holder executes and delivers to the Company an agreement reasonably
satisfactory to the Company to indemnify the Company from any loss incurred by
it in connection with such Debenture.

         16. PAYMENT OF EXPENSES; ISSUE TAXES. The Company agrees to pay all
debts and expenses, including attorneys' fees, which may be incurred by the
Holder in enforcing the provisions of this Debenture and/or collecting any
amount due under this Debenture, the Purchase Agreement, any Warrant or the
Registration Rights Agreement. The Company shall pay any and all issue and other
taxes (excluding any income, franchise or similar taxes) that maybe payable in
respect of any issue or delivery of shares of Common Stock on conversion of any
Debenture pursuant hereto.

         17. DEFAULTS. If one or more of the following described "Events of
Default" shall occur:

          (a)  The Company shall default in the payment of (i) interest on this
               Debenture or any other Debenture issued pursuant to the Purchase
               Agreement (subject to the Company's option to pay PIK Interest),
               and such default shall continue for five (5) business days after
               the

                                       12
<PAGE>

               due date thereof, or (ii) the principal of this Debenture or any
               other Debenture issued pursuant to the Purchase Agreement; or

          (b)  Any of the representations or warranties made by the Company
               herein, in the Purchase Agreement, the Registration Rights
               Agreement, any Warrant or in any certificate or financial or
               other statements heretofore or hereafter furnished by or on
               behalf of the Company in connection with the execution and
               delivery of this Debenture or such other documents shall be false
               or misleading in any material respect at the time made and
               written notice of such breach shall have been given to the
               Company by the Holders of at least 25% of the aggregate
               Outstanding Principal Amount of the Debentures then outstanding;
               or

          (c)  The Company shall fail to materially perform or observe any
               covenant or agreement in the Purchase Agreement or the
               Registration Rights Agreement, or any other covenant, term,
               provision, condition, agreement or obligation of the Company
               under this Debenture and such failure shall continue uncured for
               a period of ten (10) business days after notice of such failure
               from the Holders of at least 25% of the Aggregate Outstanding
               Principal Amount of Debentures then outstanding; or

          (d)  The Company shall (1) become insolvent; (2) admit in writing its
               inability to pay its debts generally as they mature; (3) make an
               assignment for the benefit of creditors or commence proceedings
               for its dissolution; or (4) apply for or consent to the
               appointment of a trustee, liquidator or receiver for it or for a
               substantial part of its property or business; or

          (e)  A trustee, liquidator or receiver shall be appointed for the
               Company or for a substantial part of its property or business
               without its consent and shall not be discharged within forty-five
               (45) days after such appointment; or

          (f)  Any governmental agency or any court of competent jurisdiction at
               the instance of any governmental agency shall assume custody or
               control of the whole or any substantial portion of the properties
               or assets of the Company and shall not be dismissed within
               forty-five (45) days thereafter; or

          (g)  The Company shall sell or otherwise transfer all or substantially
               all of its assets; or

          (h)  Bankruptcy, reorganization, insolvency or liquidation proceedings
               or other proceedings, or relief under any bankruptcy law or any
               law for the relief of debt shall be instituted by or against the
               Company and, if instituted against the Company shall not be

                                       13
<PAGE>

               dismissed within forty-five (45) days after such institution, or
               the Company shall by any action or answer approve of, consent to,
               or acquiesce in any such proceedings or admit to any material
               allegations of, or default in answering a petition filed in any
               such proceeding; or

          (i)  the Senior Lenders shall have accelerated the Senior Debt (as
               defined in the Purchase Agreement); or

          (j)  The Company shall be in default of any other of its indebtedness
               exceeding $1,000,000, or any other event shall have occurred, and
               as a result thereof the holders thereof shall have accelerated or
               shall have the right (upon the giving of notice, the passage of
               time, or both) to accelerate such indebtedness; or

          (k)  A "going private" transaction under Rule 13e-3 promulgated
               pursuant to the Exchange Act shall have been announced; or

          (l)  A tender offer by the Company under Rule 13e-4 promulgated
               pursuant to the Exchange Act shall have been announced;

         THEN, or at any time thereafter, and in each and every such case,
unless such Event of Default shall have been waived in writing by the Holder
(which waiver shall not be deemed to be a waiver of any subsequent default) at
the option of the Holder and in the Holder's sole discretion, the Holder may
consider the Debenture immediately due and payable, without presentment, demand,
protest or notice of any kind, all of which are hereby expressly waived,
anything herein or in any other instruments contained to the contrary
notwithstanding, and the Holder may immediately, and without expiration of any
period of grace, enforce any and all of the Holder's rights and remedies
provided herein or any other rights or remedies afforded by law. In such event,
the Debenture shall be redeemed at the greater of (i) a redemption price per
Debenture equal to 110% of the Outstanding Principal Amount of the Debenture,
plus accrued but unpaid interest and default payments on the Debenture and (ii)
the cash value that the Holder would be entitled to receive upon conversion of
the Debenture at the Conversion Price in existence on such date, without regard
to Section 12, and the subsequent sale of the Common Stock at the Market Price
for Shares of Common Stock then existing.

         18. SAVINGS CLAUSE. In case any provision of this Debenture is held by
a court of competent jurisdiction to be excessive in scope or otherwise invalid
or unenforceable, such provision shall be adjusted rather than voided, if
possible, so that it is enforceable to the maximum extent possible, and the
validity and enforceability of the remaining provisions of this Debenture will
not in any way be affected or impaired thereby, and such provision shall remain
effective in all other jurisdictions.

         19. ENTIRE AGREEMENT. This Debenture and the agreements referred to in
this Debenture constitute the full and entire understanding and agreement
between the Company and the Holder with respect to the subject hereof. Neither
this Debenture nor

                                       14
<PAGE>

any term hereof may be amended, waived, discharged or terminated other than by a
written instrument signed by the Company and the Holder.

         20. ASSIGNMENT, ETC. The Holder (but not the Company) may without
notice, transfer or assign this Debenture or any interest herein and may
mortgage, encumber or transfer any of its rights or interest in and to this
Debenture or any part hereof and, without limitation, each assignee, transferee
and mortgagee (which may include any affiliate of the Holder) shall have the
right to transfer or assign its interest. Each such assignee, transferee and
mortgagee shall have all of the rights of the Holder under this Debenture. The
Company agrees that, subject to compliance with the Purchase Agreement, after
receipt by the Company of written notice of assignment from the Holder or from
the Holder's assignee, all principal, interest and other amounts which are then
and thereafter become due under this Debenture shall be paid to such assignee at
the place of payment designated in such notice. This Debenture shall be binding
upon the Company and its successors and affiliates and shall inure to the
benefit of the Holder and its successors and assigns.

         21. NO WAIVER. No failure on the part of the Holder to exercise, and no
delay in exercising any right, remedy or power hereunder shall operate as a
waiver thereof, nor shall any single or partial exercise by the Holder of any
right, remedy or power hereunder preclude any other or future exercise of any
other right, remedy or power. Each and every right, remedy or power hereby
granted to the Holder or allowed it by law or other agreement shall be
cumulative and not exclusive of any other, and may be exercised by the Holder
from time to time.

         22. CERTIFICATE. The Company shall, upon the written request at any
time of any Holder of Debentures, furnish or cause to be furnished to such
Holder a certificate prepared by the chief financial officer of Company setting
forth any adjustments or readjustments of the Conversion Price pursuant to this
Debenture and any right of the Holder to receive additional shares of Common
Stock or any other equity or debt security pursuant to Section 7.

         23. NOTICES. The Company shall distribute to the Holders of Debentures
copies of all notices, materials, annual and quarterly reports, proxy
statements, information statements and any other documents distributed generally
to the holders of shares of Common Stock of the Company, at such times and by
such method as such documents are distributed to such holders of such Common
Stock, but shall not directly or indirectly provide material non-public
information to the Holder without such Holder's prior written consent.

         24. SPECIFIC ENFORCEMENT. The Company agrees that irreparable damage
would occur in the event that any of the provisions of this Debenture were not
performed in accordance with their specific terms or were otherwise breached. It
is accordingly agreed that the Holders of Debentures shall be entitled to swift
specific performance, injunctive relief or other equitable remedies to prevent
or cure breaches of the provisions of this Debenture and to enforce specifically
the terms and provisions hereof, this being

                                       15
<PAGE>

in addition to any other remedy to which any of them may be entitled under
agreement, at law or in equity.

         25. MISCELLANEOUS. Unless otherwise provided herein, any notice or
other communication to a party hereunder shall be sufficiently given if in
writing and personally delivered, facsimiled or mailed to said party by
certified mail, return receipt requested, at its address set forth herein or
such other address as either may designate for itself in such notice to the
other and communications shall be deemed to have been received when delivered
personally or, if sent by mail or facsimile, then when actually received by the
party to whom it is addressed. Whenever the sense of this Debenture requires,
words in the singular shall be deemed to include the plural and words in the
plural shall be deemed to include the singular. Paragraph headings are for
convenience only and shall not affect the meaning of this document.

         26. GOVERNING LAW; CONSENT TO JURISDICTION. This Debenture shall be
governed by and construed and enforced in accordance with the laws of the State
of New York applicable to contracts to be executed and performed entirely within
such state. The Company (i) hereby irrevocably submits to the exclusive
jurisdiction of the state and federal court located in New York County, New York
for the purposes of any suit, action or proceeding arising out of or related to
this Debenture and (ii) hereby waives, and agrees not to assert in any such
suit, action or proceeding, any claim that it is not personally subject to the
jurisdiction of such court, that the suit, action or proceeding is brought in an
inconvenient forum or that the venue of the suit, action or proceeding is
improper. The Company consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party as provided herein and
agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing in this paragraph shall affect or limit any right to
serve process in any other manner permitted by law.

                             SIGNATURE PAGE FOLLOWS

                                       16
<PAGE>

         IN WITNESS WHEREOF, the Company has caused this instrument to be duly
executed by an officer thereunto duly authorized.

                                         ADVANCED COMMUNICATIONS GROUP, INC.

                                         By:      /s/
                                            -----------------------------------
                                                  Name:
                                                  Title:

         Signature page to 5% Convertible Debenture of ADVANCED COMMUNICATIONS
GROUP, INC.

                                       17
<PAGE>

                                    EXHIBIT 1

                      (To be Executed by Registered Holder
                         in order to Convert Debenture)

                                CONVERSION NOTICE
                                       FOR
                 5% CONVERTIBLE DEBENTURE DUE FEBRUARY 23, 2006

         The undersigned, as Holder of the 5% Convertible Debenture Due February
23, 2006 of ADVANCED COMMUNICATIONS GROUP, INC. (the "Company"), in the
outstanding principal amount of U.S. $_____________ (the "Debenture"), hereby
irrevocably elects to convert that portion of the outstanding principal amount
of the Debenture shown on the next page into shares of Common Stock, $0.0001 par
value per share (the "Common Stock"), of the Company according to the conditions
of the Debenture, as of the date written below. The undersigned hereby requests
that share certificates for the Common Stock to be issued to the undersigned
pursuant to this Conversion Notice be issued in the name of, and delivered to,
the undersigned or its designee as indicated below. If shares are to be issued
in the name of a person other than the undersigned, the undersigned will pay all
transfer taxes payable with respect thereto. No fee will be charged to the
Holder for any conversion, except for transfer taxes, if any.

Conversion Information:             NAME OF HOLDER:____________________________

                                    By: _______________________________________
                                            Print Name:
                                            Print Title:

                                            Print Address of Holder:
                                            ___________________________________
                                            ___________________________________

                                            Issue Common Stock to:_____________
                                            at:________________________________

                                            Electronically transmit and credit
                                            Common Stock to: ________ at:

                                            ___________________________________

                                            ___________________________________
                                            Date of Conversion

                                            ___________________________________
                                            Applicable Conversion Rate

                THE COMPUTATION OF THE NUMBER OF COMMON SHARES TO
                  BE RECEIVED IS SET FORTH ON THE ATTACHED PAGE

<PAGE>

PAGE 2 TO CONVERSION NOTICE FOR: ______________________________________________
                                            (NAME OF HOLDER)

<TABLE>
<CAPTION>
              COMPUTATION OF NUMBER OF COMMON SHARES TO BE RECEIVED
<S>                                                                             <C>
A.       Outstanding Principal Amount converted:                                $ ______________
B.       Accrued, unpaid interest on Outstanding Principal Amount converted:    $ ______________
C.       Default payments due Holder on Outstanding Principal Amount converted: $ ______________
                                                                                  ______________

TOTAL DOLLAR AMOUNT CONVERTED (TOTAL OF A + B + C)                              $ ______________

                                                                                =================

EXCHANGE PRICE                                                                  $ ______________

Number of Shares of Common Stock = Total dollar amount converted                $ ______________
                                   ------------------------------       =
                                         Conversion Price                       $ ______________
</TABLE>

NUMBER OF SHARES OF COMMON STOCK   =
                                      ------------------------------------

If the conversion is not being settled by DTC, please issue and deliver _____
certificate(s) for shares of Common Stock in the following amount(s):

_______________________________________________________________________________

_______________________________________________________________________________

_______________________________________________________________________________

_______________________________________________________________________________

Please issue and deliver _____ new Debenture(s) in the following amounts:

_______________________________________________________________________________

_______________________________________________________________________________

_______________________________________________________________________________

_______________________________________________________________________________

                                       2
<PAGE>

                                   EXHIBIT 2

                                  PIK STATEMENT

Date:______________

To: [NAME OF HOLDER OF DEBENTURE] ("Holder")

RE: 5% CONVERTIBLE DEBENTURE DUE FEBRUARY 23, 2006 ("DEBENTURE") OF ADVANCED
COMMUNICATIONS GROUP, INC. (THE "COMPANY"), IN THE FACE PRINCIPAL AMOUNT OF
US$_________.

                  In lieu of paying interest on the above-referenced Debenture
in coin or currency, the Company hereby elects to pay interest on the Debenture,
for the Interest Payment Date indicated below, by having the amount of such
interest added to the Outstanding Principal Amount due under the Debenture. The
Company hereby certifies to the Holder, its successors and assigns that the
Outstanding Principal Amount due under the Debenture after delivery of this PIK
Statement equals the amount indicated below. Capitalized terms used in this PIK
Statement and not otherwise defined shall have the meaning ascribed thereto in
the Debenture.

<TABLE>
<CAPTION>
<S>                                                    <C>
         Interest Payment Date:                            _____________

         Outstanding Principal Amount prior
         to issuance of this PIK Statement:             US$_____________

         PIK Interest:                                  US$_____________

         Outstanding Principal Amount after
         issuance of this PIK Statement:                US$_____________
</TABLE>

                  IN WITNESS WHEREOF, this PIK Statement has been duly executed
and delivered on the date first written above.

                                     ADVANCED COMMUNICATIONS GROUP, INC.

                                     By:
                                         ----------------------------------
                                          Name:
                                          Title:

<PAGE>

                                   SCHEDULE I

None

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}]]